# DESCRIPTION

## FIELD OF THE INVENTION

- relate to cell isolation methods

## BACKGROUND OF THE INVENTION

- motivate diabetes treatment
- describe diabetes types
- discuss current diabetes treatments
- introduce pancreatic cell populations
- discuss limitations of current cell isolation methods
- motivate cell-based therapies
- highlight need for cell surface markers

## SUMMARY OF THE INVENTION

- introduce pancreatic cell isolation method
- describe tag-free isolation of pancreatic cell subtypes
- motivate use of cell surface markers for cell isolation
- describe novel combinations of cell markers for cell isolation
- outline uses of isolated cells in diagnosis and treatment of diabetes
- describe method of isolating enriched population of pancreatic cells
- specify heterogeneous population of cells for isolation
- describe sorting of cells using cell-surface markers
- specify cell types that can be isolated using the method
- describe isolation of beta cells or beta cell progenitors
- specify cell surface markers used for isolation
- describe use of CD9 marker for isolation
- describe use of additional markers for isolation
- outline steps for isolating enriched population of pancreatic cells
- describe use of fluorescence activated cell sorting (FACS)
- specify cell types that can be isolated from human pancreatic tissue
- describe functional screening method for identifying cell-surface markers
- outline steps for functional screening method
- describe use of functional screening method for identifying markers for beta cells
- outline scope of applicability of the present invention

## DETAILED DESCRIPTION OF THE INVENTION

- introduce functional cell-capture screen (FCCS) for identifying cell surface markers
- motivate need for selective cell surface markers for tag-free isolation of desired cells
- describe limitations of current cell replacement therapy for diabetes
- introduce novel proteomics procedure for detecting and associating cell surface markers with cell functionality
- describe identification of marker combinations enriching for discrete pancreatic cell subtypes
- discuss potential applications of identified markers for diabetes cell replacement therapy
- describe use of antibody array platform to characterize cell-surface marker profile of human pancreatic islets
- discuss advantages of FCCS over other screening methods
- describe iterative use of FCCS to identify combinations of markers for purification of beta cells
- discuss potential for FCCS to be applied to other cellular contexts
- summarize benefits of FCCS for resolving heterogeneous cellular systems

### Separation Methods:

- introduce various separation techniques for isolating cells
- describe use of monoclonal antibodies for separation
- discuss various techniques for separation, including magnetic separation and fluorescence activated cell sorting
- describe use of markers, such as magnetic beads, for separation
- discuss importance of maximizing retention of viability of fraction to be collected

### Cell Culture:

- describe culture conditions for human islets

### Antibody Array:

- describe procedure for antibody array screenings

### The FCCS Procedure:

- describe FCCS procedure, including cell dissociation, blocking, and incubation on array

### Flow Cytometry:

- describe flow cytometry procedure, including cell dissociation, blocking, and staining

### Cell Preparation:

- describe preparation of cells for FCCS

### Real-Time Quantitative PCR:

- describe procedure for real-time qPCR

## EXAMPLES

### Example 1

- describe FCCS platform

### Example 2

- identify cell-surface markers in human islets
- validate markers using FACS and qPCR

### Example 3

- fractionate islet cells using identified markers
- analyze mRNA expression of cell-type specific genes

### Example 4

- screen for marker combinations that enrich for insulin-producing cells

### Example 5

- evaluate CD9/CD56 marker combination for beta cell isolation
- analyze mRNA levels of cell-type specific markers in sorted subsets
- evaluate co-occurrence of CD9 and CD56 with insulin on a single cell basis
- compare purity and yield of beta cells isolated using CD9/CD56 combination vs. CD9 alone

